1. Introduction {#s0005}
===============

In individuals vulnerable to depression and suicide an exaggerated reaction to environmental stressors, such as life events, is found in the stress-regulating systems of the brain ([@bb0225]). This hyper-reactivity stems from the interaction of genetic, early developmental and environmental factors ([@bb0220]). The hypothalamo-pituitary-adrenal (HPA) axis holds a prominent position in the network mediated by stress- and reward-related neurotransmitters and neuromodulators, and is significantly affected in depression ([@bb0035]) and suicide ([@bb0225]).In depression, the hypothalamic paraventricular nucleus (PVN), which is the regulating center of the HPA-axis, shows not only an increased production of corticotropin-releasing hormone (CRH) ([@bb0195], [@bb0030]), but also changes in the expression of certain CRH-activity-related receptors that render the PVN more sensitive to stress ([@bb0230]). Both increased CRH and increased corticosteroid levels may induce depressive-like behavioral changes ([@bb0125]).

Hypocretin-producing neurons are localized in the hypothalamus ([@bb0130]) and act via their two G-protein-coupled receptors, hypocretin receptor-1 and -2 (Hcrt-receptor-1 and Hcrt-receptor-2) ([@bb0205]). Hypocretin projections and Hcrt-receptors are found in many brain areas, including the prefrontal cortex (PFC) ([@bb0185]). It is of interest to note that the neurophysiological and behavioral processes regulated by hypocretin, such as the sleep-wake cycle, food intake, sexual behavior, and stress response, are severely affected in depression ([@bb0165]). Several studies have indicated the possible involvement of the hypocretin system in depression with suicide. For example, reduced CSF hypocretin levels were observed in suicidal patients with major depressive disorder (MDD) compared with patients suffering from adjustment disorder or dysthymia with suicide attempts ([@bb0050]). In addition, significant negative correlations were found between CSF-hypocretin levels and the symptoms of lassitude (difficulty to initiate activities) and slowness of movement, as well as the ratings of global illness ([@bb0055]). Hypocretin has close functional interactions with the HPA-axis. In rat, CRH directly stimulates the release of hypocretin during acute stress ([@bb0240]). Hcrt-receptor antagonists were found to attenuate anxiety and panic-like behaviors associated with stress or hyperarousal states in rat ([@bb0135], [@bb0040]). Moreover, the changes in the transcripts for the Hcrt-receptor-1 and Hcrt-receptor-2 were found to be divergent, i.e. Hcrt-receptor-1 increased, while Hcrt-receptor-2 decreased in the basolateral amygdala in chronically stressed c57bl/6 mice ([@bb0020]). A clinical study of single-nucleotide polymorphisms suggested that the hcrt-receptor-1 gene, or a linked locus, may modulate the risk for mood disorders ([@bb0200]). This possibility was confirmed in hcrt-receptor-1 knockout mice, which showed increased anxiety-like behavior and altered depression-like behaviors ([@bb0005]). These data indicate that the hypocretin system may have a bidirectional regulatory capacity in terms of the stress response.

In light of the data mentioned above, we hypothesized that the hypocretin/orexin system may play a role in the pathogenesis of depression and suicide, possibly by interaction with the HPA-axis. To test this possibility, we measured hypocretin-1 expression in its production area, the postmortem hypothalamus. Second, Hcrt-receptors-mRNA content was determined in the PFC of depressive patients, some of whom had committed suicide. Finally, we determined prepro-hypocretin-mRNA and CRH-mRNA in the hypothalamus and Hcrt-receptors-mRNA levels in the frontal cortex in a frequently used animal model for depression, i.e. chronic unpredictable mild stress (CUMS) rats. Because of the clear sex differences in depression and suicide, special attention was given to the possible sex differences, both in the human and in the animal studies ([@bb0025]).

2. Materials and Methods {#s0010}
========================

2.1. Part I: Post-mortem Brain Material Study {#s0015}
---------------------------------------------

In total, 120 human post-mortem samples were studied: 32 hypothalami and 52 cortex samples from the Netherlands Brain Bank (NBB), and 36 cortex samples from the Stanley Medical Research Institute (SMRI). Informed consent for a brain autopsy and for the use of the brain material and medical records for research purposes was given by the donor or their next of kin.

The chronic mood disorder patients and their controls were well-matched for confounding factors, including age, sex, postmortem delay, fixation time, clock time of death, month of death, CSF-pH (a measure of agonal state), brain weight and Braak stages of Alzheimer\'s pathology ([@bb0045]). Clinico-pathological details and p-values of matching are given in [Table 1](#t0005){ref-type="table"} and [Supplementary Table 1](#ec0005){ref-type="supplementary-material"}, [Supplementary Table 2](#ec0010){ref-type="supplementary-material"}. The diagnosis of MDD or bipolar disorder (BD) was confirmed according to the Diagnostic and Statistical Manual of Mental Disorders IV by qualified psychiatrists using the extensive medical records of the NBB, which also contained well-documented diagnoses and onset of depression from psychiatric clinics. Exclusion criteria for control subjects were in the first place the use of corticosteroids, as they inhibit the CRH cells in the human hypothalamus ([@bb0235]), which may subsequently influence the hypocretin system ([@bb0060]). In addition, primary neurological or psychiatric diseases were exclusion criteria, unless stated otherwise. The absence of pathology was verified in all subjects by a systematic neuropathological analysis ([@bb0095], [@bb0100]).

### 2.1.1. Immunocytochemistry and Quantification {#s0020}

The hypothalami were fixed in 10% PBS (pH 7.4) formalin at room temperature and were paraffin-embedded and serially-sectioned at 6 μm in rostro-caudal direction. Hypothalami of 16 mood disorder patients, i.e. 9 MDD and 7 BD patients, and 16 control subjects were used. Every 100th section of 6 μm thickness in the expected hypocretin cell area was stained using a hypocretin-1 antibody (catalog no. H-003-30, Phoenix Pharmaceuticals, Inc., Belmont, CA, USA) at 1:20,000 dilution. The specificity of the antibody had been confirmed in our previous study ([@bb0095]). In addition, we stained the hypothalamus of a narcoleptic patient as a negative control whose hypothalamus was indeed virtually devoid of hypocretin-1-immunoreactive (ir) neurons.

Hypocretin-1-ir was quantified by the image analysis procedure described in our previous studies ([@bb0100]). In brief, the set-up consisted of an image analysis system (Image Proversion 6.3, Media Cybernetics, Rockville, USA) connected to a black and white camera (SONY XC-77E) mounted on a microscope (Zeis Axios-kop with Plan-NEOFLUAR Zeiss objectives, Carl Zeiss GmbH, Jena, Germany). The hypothalamus area covered by hypocretin-stained neurons was outlined manually at a 20 × objective. The threshold for the positive signal was set at twice the optical density (OD) of the background. The computer determined the OD of the pixels and percentage surface area covered by the signal (area mask). The integrated optical density (IOD) was calculated by multiplying the OD by the masked area corrected for background. For each subject, the total IOD was calculated as the final parameter for the total amount of Hypocretin-1-ir, by a conversion program based upon multiplication of the separate IOD by sample frequency of the sections, as described previously ([@bb0105]). Completeness of the hypocretin-1-ir in the hypothalamus was confirmed by graphically presenting the IODs measured in every section from rostral to caudal, with a line drawn by the excel trend-line option 'Moving Average'. The value under each curve showed the total IOD of the subject (see [Fig. 1](#f0005){ref-type="fig"}A--B). The total IOD of hypothalamic hypocretin-1-ir as determined by computer-assisted morphometry is not only an objective method but also less time-consuming than neuron-counting. In addition, the IOD shows a good positive correlation with neuron-counting (for 35 sections of 2 patients and 2 controls, rho = 0.781, p \< 0.001), performed in the way we described previously ([@bb0095]).

### 2.1.2. Quantitative PCR (qPCR) for mRNA Expression of Hcrt-receptors {#s0025}

In our present study 50 μm cryostat sections of anterior cingulate cortex (ACC) or dorsal lateral prefrontal cortex (DLPFC) were cut from the left side of the cortex and the grey matter containing all six layers was isolated as described before ([@bb0100]). Levels of Hcrt-receptor-1- and Hcrt-receptor-2-mRNA were determined by qPCR. Information regarding gene selection and primers are shown in [Supplementary Table 3](#ec0015){ref-type="supplementary-material"}. RNA isolation, cDNA synthesis and qPCR were performed as described before ([@bb0230]).

In addition, a normalization strategy was used to remove sampling-related differences in RNA quantity ([@bb0230]). The expression of target genes was normalized using the sets of stable reference genes, including actin-beta (ACTb), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), hypoxanthine phosphoribosyltransferase 1 (HPRT1), and ubiquitin-C for the postmortem human brain study, while ACTb, GAPDH, HPRT1, and elongation factor-1 alpha (EF1α) for the animal study (see below).

2.2. Part II: Animal Study {#s0030}
--------------------------

Adult Sprague Dawley male (n = 12, 280--300 g, \~ 8 weeks of age) and female (n = 24, 230--250 g, \~ 8 weeks of age) rats were randomly divided into a control and a CUMS group. CUMS was applied according to our previous study ([@bb0145]). Briefly: this involved a three-week daily exposure to alternating stressors along with occasional overnight stressors. The following stressors were given in random order: damp bedding (300 ml of water spilled in the bedding), 40°-cage-tilt along the vertical axis, paired housing, exposure to an empty water bottle for 1 h immediately following a period of acute water deprivation (25 h from 0900 h until 1000 h the next day), stroboscopic illumination (300 flashes/min), and white noise. Body weight was assessed weekly during the CUMS procedure, and an open field test for anxiety-behavior ([@bb0075]) and sucrose preference test for depression-like behavior such as anhedonia ([@bb0065]) were performed following the CUMS paradigm. In the open field test we measured the distance the rat travelled in the field, the time spent in the central squares, together with the number of grid lines crossed. In the 5% sucrose preference test sucrose preference was determined by the ratio of the weight of sucrose solution versus water consumed during the 24 h.

### 2.2.1. Tissue Collection {#s0035}

Rats were sacrificed by decapitation between 0900 h and 1000 h upon conclusion of the behavioral tests. Female rats, both of the control and CUMS groups, were sacrificed, in equal numbers, in proestrus or diestrus. Trunk blood, hypothalamus and frontal cortex were collected. The hypothalamus and frontal lobe were immediately dissected, frozen in liquid nitrogen and stored at − 80 °C until assayed.

All animal experimental procedures were approved by the local animal care committee of Zhejiang University in accordance with the relevant regulations and laws.

### 2.2.2. Sample Measurement {#s0040}

Plasma corticosterone (CORT) levels were assayed by ELISA (RE52211, IBL Corporation, USA). Hypothalamic mRNA levels of prepro-hypocretin, Hcrt-receptor-1, Hcrt-receptor-2 and CRH, and frontal cortex mRNA levels of Hcrt-receptor-1 and Hcrt-receptor-2 were determined by qPCR. The primers were designed by Primer Premier (version 5.0) to amplify specific amplicons. Sequences and size of the primer pairs are shown in [Supplementary Table 3](#ec0015){ref-type="supplementary-material"}. The RNA isolation and qPCR were performed as described before by our group ([@bb0230]).

2.3. Statistics {#s0045}
---------------

As the data were not always normally distributed, non-parametric tests were applied. Differences between 2 groups were tested using the Mann-Whitney *U* test. Differences among the 3 groups were first tested with Kruskal-Wallis (K-W), and if a significant difference was identified, the difference between 2 groups was checked with the Mann-Whitney *U* test. Generalized linear model (GLM) was applied to analyze the contribution of certain factors to the changes observed in Hypocretin-1-ir (see [Section 3](#s0050){ref-type="sec"}). Correlations were examined with the Spearman\'s test. Differences in clock time and month of death were analyzed with the Mardia-Watson-Wheeler test. All tests were 2-tailed, p-values ≤ 0.05 were considered to be significant, while p-value \< 0.1 and \> 0.05 was considered to be a trend.

3. Results {#s0050}
==========

3.1. Postmortem Human Brain Material {#s0055}
------------------------------------

### 3.1.1. Hypocretin-1 Immunocytochemistry {#s0060}

Hypocretin-1-ir neurons showed the same distribution pattern as described before ([@bb0095]), and hypocretin-1-ir was present in the cytoplasm and fibers of hypothalamic neurons, both in controls and depressive patients ([Fig. 1](#f0005){ref-type="fig"}C--F). Data are presented as median (25th--75th percentile). The IOD of hypocretin-1-ir showed a significantly higher level in the depression group compared with the control group (depression: 0.23 (0.14--0.26); controls: 0·17 (0.10--0.22), p = 0.050), which appeared to be due to the female depressive patients, who showed significantly (40%) higher IOD values (0.27 (0.22--0.37)) than the matched female controls (0.19 (0.09--0.21); p = 0.022), while the IOD of hypocretin-1-ir of male depressive patients (0.17 (0.13--0.23)) showed no significant differences from the control male subjects (0.15 (0.11--0.22); p = 0.406) ([Fig. 2](#f0010){ref-type="fig"}A). GLM was applied with depression and sex as the main factors to investigate the effect of these two factors on hypocretin-1-ir and the interaction between them. GLM revealed that the interaction between depression and sex was significant (p = 0.041). The main effect of depression on hypocretin-1-ir remained significant (p = 0.003), as well as the effect of sex (p = 0.004).

There was no difference in hypocretin-1-ir IOD between the MDD and BD subgroups (p = 0.874), either between female and male subjects within the control group (p = 0.652) or between female and male subjects within the control group (p = 0.875). Furthermore, there were no significant correlations between the IOD of hypocretin-1-ir with age or with the duration of depression (p ≥ 0.15).

### 3.1.2. Hypocretin-1-ir Day-Night Fluctuation {#s0065}

In the control group, the IOD of hypocretin-1-ir was significantly (40%) higher for those with a clock time of death at night (0.20 (0.15--0.22), 1900 h--0700 h) than for those with a clock time of death during the daytime (0.09 (0.07--0.17); p = 0.031), whereas such a difference was not present in the depression subjects (nighttime: median = 0.23; daytime: median = 0.18; p = 0.382, [Fig. 2](#f0010){ref-type="fig"}B). The time segmentation was based upon a previous study on the diurnal rhythm of CSF hypocretin-1 levels ([@bb0210]). The daytime and nighttime control subgroups did not differ significantly in terms of possible confounders, i.e. age, sex, PMD, FT, or CSF-pH (p ≥ 0.137).

### 3.1.3. The mRNA Expression of Hcrt Receptors in the ACC and DL PFC {#s0070}

In the cortex samples of the relatively *younger* patients of the SMRI series (depression: 42 years (24--63 years); controls 46 years (24--63 years), [Supplementary Table 2](#ec0010){ref-type="supplementary-material"}), both Hcrt-receptor-1- and Hcrt-receptor-2-mRNA expression were detectable in the ACC and the DLPFC. No significant differences in ACC Hcrt-receptor-1-mRNA expression were seen among the 3 groups, i.e. depressive patients who had committed suicide, depressive patients who had died of causes other than suicide, and control subjects (K-W: Hcrt-receptor-1, p = 0.102), but there was a trend for changes in Hcrt-receptor-2-mRNA in these 3 groups (K-W: p = 0.085). We observed a significant difference in Hcrt-receptor-2-mRNA expression among these 3 groups in male subjects (K-W: p = 0.035), which was subsequently found to be due to the significantly (38%) higher Hcrt-receptor-2-mRNA levels in male suicide MDD patients (n = 10) compared with male controls (n = 8, p = 0.015, [Fig. 2](#f0010){ref-type="fig"}C). Please note that although we did not observe similar significant changes in female subjects or in male subjects who died of causes other than suicide (K-W: Hcrt-receptors, p ≥ 0.222), the number of these subgroups was too small to draw a firm conclusion in relation to sex difference and/or suicide. In the DLPFC, Hcrt-receptor-1-mRNA expression showed a significant negative correlation with age in the control group (rho = − 0.887, p = 0.001). No significant changes in Hcrt-receptors-mRNA expression in the DLPFC were observed, either among the 3 entire (female + male) groups, i.e. depressive patients who had committed suicide, depressive patients who had died of causes other than suicide, and control subjects, or among 3 different female or male subgroups (K-W: Hcrt-receptors, p ≥ 0.345).

In cortex samples of the relatively *older* patients (depression: 78 years (45--96 years); controls 73 years (45--90 years), [Supplementary Table 1](#ec0005){ref-type="supplementary-material"}), which contained only non-suicide depressive patients, Hcrt-receptor-1-mRNA expression was only detectable in the ACC, while Hcrt-receptor-2-mRNA expression was only detectable in the DLPFC, both in the control and in the depression group. In the ACC of these non-suicide depressive patients there was a trend (p = 0.068, [Fig. 2](#f0010){ref-type="fig"}D) towards lower Hcrt-receptor-1-mRNA expression compared with the controls. In the DLPFC, no significant differences in Hcrt-receptor-2-mRNA expression were found between the non-suicide depressive patients and the control group (p = 0.894). There were no sex differences in HCRTs either in the ACC or in the DLPFC (p ≥ 0.209). There was no significant correlation between the duration of depression and the Hcrt-receptors-mRNA levels in the ACC or DLPFC (p ≥ 0.401).

### 3.1.4. The CUMS Animals {#s0075}

Although the body weight of both female and male rats showed, as expected, a diminished increase during and after the CUMS procedure ([Supplementary Fig. 1](#f0020){ref-type="graphic"}A), only the female CUMS rats showed significant depression-like (sucrose preference tests, [Supplementary Fig. 1](#f0020){ref-type="graphic"}B) and anxiety-like (open field test) behaviors ([Supplementary Fig. 1](#f0020){ref-type="graphic"}C--E). Plasma CORT levels were significantly increased both in female and male (p ≤ 0.008) CUMS rats ([Fig. 3](#f0015){ref-type="fig"}A). It should be noted that we pooled these female rats for the correlation analysis, since we did not observe a significant difference in the plasma CORT levels, hypothalamic mRNA levels of prepro-hypocretin, Hcrt-receptor-1, Hcrt-receptor-2 and CRH, and frontal cortex mRNA levels of Hcrt-receptor-1 and Hcrt-receptor-2 between female rats sacrificed in proestrus and in diestrus, we pooled these female rats for the correlation analysis. The Hcrt-receptor-1-mRNA expression was significantly higher in the frontal cortex of female CUMS rats (0.012 (0.009--0.017)), compared with the female control rats (0.008 (0.007--0.010); p = 0.019, [Fig. 3](#f0015){ref-type="fig"}B), while male rats did not show significant alterations in these molecules after CUMS (p ≥ 0.328). There were no significant differences in the mRNA expression of prepro-hypocretin, Hcrt-receptor-1, Hcrt-receptor-2 or CRH in the hypothalamus between the CUMS and the control rats in either sex (p ≥ 0.234). However, female CUMS rats showed a significant positive correlation between the mRNA levels of CRH and prepro-hypocretin (p = 0.007, rho = 0.775, [Fig. 3](#f0015){ref-type="fig"}C), which was absent in male CUMS rats (p = 0.517, rho = − 0.238, [Fig. 3](#f0015){ref-type="fig"}D).

4. Discussion {#s0080}
=============

Our study shows, for the first time in postmortem human brain, that hypothalamic hypocretin/orexin is increased in female - but not in male - depressive patients. In addition, there was a diurnal fluctuation in hypothalamic hypocretin-1-ir in the control subjects, which was absent in depression. Moreover, we observed that Hcrt-receptor-mRNA expression showed differences in the ACC and DLPFC depending on age. Male depressive patients who had committed suicide had significantly increased ACC Hcrt-receptor-2-mRNA expression. Our data thus indicate sex-, brain area-, age-, and potentially suicide-related changes in the hypocretin/orexin system in depression. Finally, a significant positive correlation between hypothalamic CRH-mRNA and prepro-hypocretin-mRNA and a significant increase in Hcrt-receptor-1-mRNA expression in the frontal cortex in female - but not male - CUMS rats strengthen the presence of sexually dimorphic hypocretin/orexin system changes in mood disorder.

4.1. Hypocretin-ir in the Hypothalamus in Depression {#s0085}
----------------------------------------------------

It should be noted that the increased IOD of hypocretin-ir may indicate an increase in either hypocretin-expressing neuron number (related to the area stained) and/or staining intensity (measured as OD). An increase of either of these parameters indicates an increased expression of hypocretin protein levels. The significantly increased hypocretin-ir in female depressive patients indicates that hypocretin may play a key role in the etiology of depression, which is more prevalent in females than in males ([@bb0190]). As we have indicated in the Introduction section, studies have found that Hcrt-receptor-1 gene, or a linked locus, may modulate the risk for mood disorders ([@bb0200]) and Hcrt-receptor-1 gene knockout mice showed increased anxiety-like behavior and altered depression-like behaviors ([@bb0005]). One may thus speculate that the higher levels of hypocretin-1-ir in female patients may enhance depressive symptoms. It should be noted that since all the female subjects studied in our study were in their postmenopausal stage, one would not expect to see the hot flash-related hypocretin changes reported earlier ([@bb0090]).

The sex difference in the alterations of hypocretin, which happens in the framework of the stress-hypothesis, was further supported by our animal study, showing a significant positive correlation between hypothalamic prepro-hypocretin-mRNA and CRH-mRNA only in female CUMS rats. In view of this, it is of interest to note that the dual Hcrt-receptor antagonist almorexant was found to prevent HPA axis dysregulation caused by CUMS and offers evidence for the possibility that pharmacological blockade of the hypocretin system induces a robust antidepressant-like effect as well as the restoration of the stress-related HPA axis defect ([@bb0175]). It should be noted, however, that other animal models of depression showed different results in terms of changes in the hypocretin system, such as the genetically depressed Wistar-Kyoto male rats, which showed a lower number and size of hypocretin-1 neurons than its control Wistar male rats ([@bb0015]). In another genetically depressed rat model, i.e. the Flinders Sensitive Line (FSL), the number of hypothalamic hypocretin-positive neurons was higher in female FSL rats than in the female control rats, i.e. Flinders Resistant Line (FRL) although this publication by Mikrouli et al. offers no data on male rats ([@bb0155]). It is a frequent phenomenon that animal models tend to mimic "just a few symptoms rather than a complete psychiatric disorder". This is a reason to validate the data obtained in animal models on human postmortem material.

We found a clear day-night fluctuation in hypothalamic hypocretin-1-ir in the control subjects, with higher levels at night, which is similar to the pattern reported for lumbar puncture CSF hypocretin-1 levels obtained by continuous in vivo sampling ([@bb0210]). These findings are in agreement with the concept that hypocretin neurons may play a key role in sleep-wake regulation ([@bb0215]), and the absence of the day-night hypocretin-1-ir fluctuation in depression may thus relate to the frequently occurring symptoms of sleep disorders in this condition. It should be noted that in our earlier research we demonstrated a clear diurnal rhythm in the biological clock, the suprachiasmatic nucleus (SCN), for its main neuropeptide, vasopressin, both on the protein level ([@bb0120]) and on the mRNA level ([@bb0260]) in postmortem material, when the patients were grouped according to time of death. Interestingly, a direct projection from the SCN onto the hypocretin neurons was observed in the brains of rat and human ([@bb0010]), which indicates that the SCN may directly regulate the function of hypocretin-immunoreactive neurons. Our finding of the absence of a diurnal hypocretin rhythm in depression agrees with our earlier observation of a diminished SCN function in depression ([@bb0260]). Our data ([@bb0260]) and those of others ([@bb0140]) thus also show that postmortem studies can indeed reflect the day-night fluctuations during life.

It is of interest to note that in rats the maximal activity of the hypocretin system takes place in their active period, i.e. at night ([@bb0160], [@bb0245]) Surprisingly, we found the highest hypocretin-1-ir levels in the human hypothalamus at night. However, this observation agrees with two human studies that reported the lowest CSF hypocretin levels during the daytime ([@bb0210], [@bb0110]). This means that the nocturnal elevation of hypocretin-1-ir in the hypothalamus is not simply due to a lack of transport or secretion. A similar phenomenon was observed for melatonin, which is also involved in sleep-wake control: in rats, melatonin levels increase during the dark period (their active phase) and decrease during the light period (rest phase) ([@bb0115]), while in humans its levels increase during the dark period (rest phase) and decrease during the light period (active phase) ([@bb0250]). The possibility that the diurnal regulation systems act in a different way in a diurnal and a nocturnal species (such as rodents) warrants further investigation.

A recent study showed an age-related decline in the number of hypothalamic hypocretin neurons in the range from 0 to 60 years of age in control subjects ([@bb0130]). We did not find such a correlation, but it should be noted that, unlike in the study by others, the control subjects we studied did not contain very young ages.

4.2. PFC Hcrt-receptors in Depression and in Relation to Suicide {#s0090}
----------------------------------------------------------------

Earlier, our group found, with NBB cortex samples (depression patients without suicide), that the ACC seems to be more vulnerable than the DLPFC to alterations in depression-related molecules, such as nitric oxide synthase, gamma-aminobutyric acid and glutamate ([@bb0100], [@bb0255]). In our study, with NBB cortex samples, again we observed a trend for lower Hcrt-receptor-1-mRNA expression in the ACC in depression but no changes in Hcrt-receptors in the DLPFC. The novel finding with SMRI cortex samples (containing depressive patients who committed suicide or died of causes other than suicide) that there was a significantly increased Hcrt-receptor-2-mRNA expression in the ACC, but not in the DLPFC, in male MDD patients who had committed suicide is in agreement with previous findings that the ACC is more vulnerable to suicide than the DLPFC ([@bb0255], [@bb0085]) and that there is a sex difference in the prevalence of suicide ([@bb0150]). Our data concerning increased ACC Hcrt-receptor-2-mRNA expression in male suicide patients are thus interesting, although too limited for a final conclusion. They do represent, however, a strong rationale for further studies on this topic. Finally, the decreased Hcrt-receptor-1-mRNA expression with aging we observed in the DLPFC may at least partly explain the findings that in SMRI cortex samples (younger) both Hcrt-receptors were detectable in ACC and DLPFC, while in the NBB series (older) Hcrt-receptor-1-mRNA expression was only detectable in ACC and Hcrt-receptor-2-mRNA expression was only detectable in the DLPFC.

Some concerns of the present postmortem brain material study should be mentioned. We did not find significant differences in the hypothalamic hypocretin-1-ir expression between MDD and BD patients, which is in accordance with our previous findings for CRH, AVP and OXT and for receptors in the hypothalamus ([@bb0030], [@bb0230]), although a final conclusion on this phenomenon should be based upon a larger sample size. Secondly, one of the inherent potential confounding factors in a postmortem study is medication use. However, we do not think that our main conclusions are cofounded by antidepressants, since increased hypothalamic hypocretin-1-ir was only observed in female depressive patients and increased expression of Hcrt-receptor-2-mRNA in the ACC was only observed in male depressive suicides, although all the depressive groups had been on antidepressants. In addition, animal studies showed that benzodiazepines ([@bb0180]), haloperidol ([@bb0080]) and fluoxetine ([@bb0170]), taken by the depressive patients in the present study, may inhibit hypocretin neurons and/or decrease hypocretin levels. Therefore, had antidepressants interfered with our measurements, this would have led to an underestimation of the increased hypocretin-1 levels observed in female depressive patients. It is noted that Calegare et al. found that sub-chronic treatment of adult *male* rats with fluoxetine increased the levels of prepro-hypocretin mRNA in the hypothalamus without affecting the hypocretin-1 CSF levels ([@bb0070]). In our study, there were 2 out of 10 male depression patients who had taken fluoxetine, while their hypothalamic hypocretin-1-ir levels (IOD: 0.128 and 0.134) were fully within the range of the other male depression patients (IOD range from 0.103 to 0.248, median value 0.166). Finally, it should also be noted that the Hcrt-receptor data are based upon mRNA measurements and have yet to be confirmed on the protein level.

5. Conclusions {#s0095}
==============

A clear sex-related change was found in the hypothalamic hypocretin-1-ir in depression. The CUMS rat depression model did not replicate changes found in the hypocretin systems in the human brain in depression. Since sex-related changes in hypothalamic hypocretin-1-ir expression were observed in depression, this factor should be taken into account in the development of hypocretin-targeted therapeutic strategies.
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![Immunocytochemistry of hypocretin-1. A--B: representative distribution patterns of the integrated optical density (IOD) of hypocretin-1 immunoreactivity from rostral to caudal along the hypothalamus. (A) A female depression patient, (B) a male depression patient. C--F: representative hypocretin-1 staining in the hypothalamus of a female control subject. (C) A female control subject. (D) A female depression patient. (E) A male control subject and (F) a male depression patient. Bar = 0·025 mm.](gr1){#f0005}

![Changes of hypocretin-1 system in depression. A: Comparison of the amount of hypocretin-1-immunoreactivity (ir) between the entire control (CTR, n = 16) and the entire depression group (DEP, n = 16), the female CTR (n = 6) and female DEP group (n = 6), and the male CTR (n = 9) and male DEP group (n = 9). B: The amount of hypocretin-1-ir is on the left side for the CTR group (between nighttime (1900 h--0700 h, n = 9) and daytime (0700 h--1900 h, n = 7), and on the right side (n = 8 vs. n = 8) for the DEP group. The time segmentation was based upon a study on the diurnal rhythm of cerebrospinal fluid hypocretin-1 levels ([@bb0075]).\
Note the absence of a day-night fluctuation in DEP patients. C: The hypocretin (Hcrt) receptor-2-mRNA levels in the anterior cingulated cortex (ACC) of the entire group comparison, i.e. CTR (n = 12), major depressive disorder patients who committed suicide (MDD + suicide, n = 17) and MDD patients who died of causes other than suicide (MDD + non-suicide, n = 7) on the left side, and for male groups comparison on the right side.\
Note that male MDD + suicide patients (n = 10) had significantly higher Hcrt receptor-2-mRNA levels compared with male controls (n = 8). D: The Hcrt-receptor-1-mRNA levels in the ACC of these non-suicide depressive patients (n = 12) showed a trend for decrease compared with the controls (n = 12).](gr2){#f0010}

![A: Plasma corticosterone levels of control (male CTR, n = 6; female CTR, n = 12) rats and chronic unpredictable mild stress (CUMS) rats (male CUMS, n = 6; female CUMS, n = 12). B: Hypocretin (Hcrt) receptor-1-mRNA expression in frontal cortex of CTR and CUMS rats. Please note that female CUMS rats (n = 12) had significantly higher Hcrt receptor-1-mRNA levels compared with female controls (n = 12). C: There was a significant positive correlation between prepro-hypocretin-mRNA and corticotropin-releasing hormone (CRH)-mRNA in the hypothalamus of female CUMS rats (rho = 0·775, p = 0·007, n = 12). D: There was no significant correlation between prepro-hypocretin-mRNA and CRH-mRNA in the hypothalamus of male CUMS rats (rho = − 0·238, p = 0·517, n = 6).](gr3){#f0015}

###### 

Clinico-pathological information of subjects for hypothalamus study.

Table 1

  NBB         Group   Sex   Age at death/age of onset (y)   PMD (hr:min)   FT (d)   CTD     MOD    CSF pH   BW (g)   Braak stage   Medication in the past                           Medication in the last 3 months     Suicide thought   Suicide attempt   Cause of death
  ----------- ------- ----- ------------------------------- -------------- -------- ------- ------ -------- -------- ------------- ------------------------------------------------ ----------------------------------- ----------------- ----------------- ------------------------------------------------------------------------------
  92-003      MDD     F     55/2                            4:54           52       07:45   11     6.40     1320     ND            BZD, SSRI, TeCA                                  SSRI, BZD, bromocriptine            Yes               Yes               Suspected urosepsis, heart failure
  94-032      MDD     M     71/2                            16:15          38       16:15   2      ND       975      ND            ZUC, BZD, MAOI, digoxine                         None                                Yes               Yes               Probably broncho-pnemonia, next to cerebral ischaemia
  94-017      MDD     F     72/20                           22:00          39       19:00   1      ND       1287     ND            TeCA, BZD, prednison                             None                                NO                No                Bronchopneumonia, mesothelioma
  12-097      MDD     F     73/9                            5:45           61       15:30   9      6.70     1205     ND            TeCA                                             TCA, TeCA, BZD, pancuronium, Ba     No                No                Heart failure, legal euthanasia
  95-036      MDD     M     74/0.5                          62             35       17:05   3      ND       1444     ND            SSRI, BZD, cisordinol                            SSRI, BZD, cisordinol               Yes               Yes               Suicide by hanging
  02-051      MDD     M     81/34                           15:30          34       15:30   6      6.50     1345     3             None                                             Hal                                 No                No                Renal insufficiency
  11-058^a^   MDD     M     83/24                           10:40          57       05:00   7      6.50     1200     2             TCA, TeCA, Hal, Pipamperon, SSRI                 BZD, gabapentin, clonazepam, Mo     No                No                PTSS with depression, acute heart failure
  08-076      MDD     F     91/36                           5:20           36       09:05   8      6.53     1163     3             Hal, SSRI, BZD, levothyroxine                    SSRI, BZD, levothyroxine            No                No                Cachexia and dehydration by pneumonia and renal insufficiency
  08-031      MDD     F     93/63                           4:20           51       04:55   3      6.80     1023     2             SSRI, BZD                                        Mo, BZD, SSRI                       Yes               Yes               Pneumonia
  02-014      BD      M     68/26                           12:00          30       00:00   2      6.64     1424     1             Li, Hal, ZUC, MAOI                               MAOI                                No                No                Subdural hematoma
  99--118     BD      M     68/30                           5:55           33       23:15   10     6.82     1204     1             Li, SSRI                                         Li                                  Yes               No                Cardiac ischemia
  00--111     BD      M     70/35                           4:50           43       02:45   10     6.26     1490     1             Li, ZUC, valproate, BZD                          Li, ECT                             No                No                Cardiac arrest, ileus due to intestinal haemorrhage
  00-088^b^   BD      M     73/45                           5:15           36       09:30   7      6.38     1260     2             Li, BZD, SSRI, Hal, ECT, MAOI, methylphenidate   Li, SSRI, Hal, methylphenidate      Yes               No                Cachexia, dehydration
  98-010      BD      F     75/20                           4:00           38       20:45   1      ND       1123     1             TeCA, TCA                                        BZD, TeCA, SSRI, Hal, Mo            No                No                Acute abdomen secondary to a perforation of stomach/intestines due to NSAIDs
  12-048      BD      M     81/15                           6:40           60       20:00   5      6.70     1283     1             Li, prednisolon                                  Li, BZD, amitriptyline, valproate   No                No                Legal euthanasia
  12-110      BD      M     87/10                           3:15           53       23:00   10     6.39     1285     3             BZD, valproate                                   BZD, Mo, valproate                  No                No                CVA, pneumonia
  Median      --      --    76/20                           5:50           44       15:30   6      6.51     1271     --            --                                               --                                  --                --                --
  99-033      CTR     F     61                              17:45          119      23:15   12     ND       1296     0             None                                             None                                --                --                Acute heart failure, gastric blood loss
  97-042      CTR     F     65                              12:50          28       02:00   4      6.94     910      1             None                                             Adrenalin                           --                --                Cardiac arrest, pneumonia, pulmonary oedema
  99-101      CTR     M     69                              19:15          41       03:30   8      6.40     1352     1             None                                             βB, Hal, BZD                        --                --                Pneumonia
  92-049      CTR     M     71                              5:40           32       12:00   4      7.40     1250     ND            None                                             None                                --                --                Found death
  08-032      CTR     M     71                              8:55           70       03:15   3      6.64     1520     2             Mo                                               Mo                                  --                --                Pancreas carcinoma, rectum carcinoma with hepatic metastases
  98-104      CTR     F     74                              7:25           31       09:50   7      6.95     1167     2             BZD                                              BZD, βB                             --                --                Necrosis of the intestines secondary to thrombosis
  95-106      CTR     M     74                              8:00           60       13:00   11     6.75     1317     0             None                                             Dopamine                            --                --                Myocardial infarction
  06-028      CTR     M     76                              19:35          27       20:00   4      6.50     1514     3             None                                             None                                --                --                Prostate carcinoma, cardiac arrest
  94-039      CTR     M     78                              53             88       12:00   1      ND       1354     ND            None                                             Nitroglycerine                      --                --                Myocardial infarction
  99-116      CTR     M     78                              4:20           43       16:15   9      ND       1310     0             None                                             Mo, BZD                             --                --                Pancreatic cancer
  95-006      CTR     M     81                              8:25           28       04:45   1      6.70     1274     1             None                                             ND                                  --                --                Cardiogenic shock
  00-022      CTR     F     83                              7:45           34       21:00   2      6.52     1102     2             Digoxin, methimazole                             Digoxin, methimazole                --                --                Acute myocardial infarction
  09-075      CTR     M     88                              7:00           44       02:25   10     6.76     1230     3             Salbutamol, prednisolone,                        Mo, Hal, goserelin                  --                --                Cachexia and dehydration by rectum carcinoma and prostate carcinoma
  09-001      CTR     M     88                              4:43           51       19:47   1      6.17     1418     2             None                                             None                                --                --                Gastro-intestinal bleeding
  08-105      CTR     F     89                              3:52           58       12:10   12     7.30     1258     3             prednisolone                                     Hal, digoxine, Mo                   --                --                Pneumonia
  08-054      CTR     F     92                              7:00           67       09:45   6      6.55     1230     1             Digoxine, prednison                              prednison                           --                --                Acute death, probably pulmonary embolism
  Median      --      --    77                              7:52           43       12:00   5      6.7      1285     --            --                                               --                                  --                --                --
  p-Value     --      --    0.616                           0.361          0.780    0.711   0.93   0.137    0.515    --            --                                               --                                  --                --                --

Note: βB, beta-blocker; Ba, barbiturate; BD, bipolar disorder; Braak stage, progression of pathological changes for Alzheimer\'s disease according to [@bb0045]; BW, brain weight; BZD, benzodiazepine; CSF, cerebrospinal fluid; CTD, clock time at death; CTR, control; CVA, cerebrovascular accident; ECT, electroshock treatment; F, female; FT(d), fixation time in days; F, female; Hal, haloperidol; Li, lithium; M, male; MAOI, monoamine oxidase inhibitor; MDD, major depressive disorder; Mo, morphine; MOD, month of death; NBB, Netherlands Brain Bank; ND, no data; None, no medication; NSAIDs, nonsteroidal anti-inflammatory drugs; PMD, postmortem delay; PTSS, posttraumatische stressstoornis; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant; TeCA, tetracyclic antidepressants; ZUC, zuclopenthixol. a: Patient also be diagnosis with post traumatic stress syndrome. b: Patient also be diagnosis with old cerebrovascular accident mildly demanded.
